Sort
82,697 grants matching “vaccine development”
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
$997,662Ian James Amanna · Najit Technologies, Inc. · U44 · FY2022 · AI
Characterization of CAR-directed T-cells to suppress HIV-1 in vivo
$997,645Scott G Kitchen · University Of California Los Angeles · U19 · FY2016 · AI
Automating mosquito microdissection for a malaria PfSPZ vaccine
$997,637Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2017 · AI
Protection Against Inhalation Anthrax with Inactivated Spores
$997,616Donald G. Guiney · University Of California, San Diego · U01 · FY2009 · AI
Improved scalability, sensitivity, and interpretability of pathogen detection, including SARS-CoV-2, in wastewater using high-throughput, highly multiplexed digital array PCR technology
$997,507Rachel Todd Noble · Univ Of North Carolina Chapel Hill · U01 · FY2021 · DA
Improved Influenza Vaccine Efficacy Through Infection Mimicry
$997,500Kathryn Kosuda · Vaxess Technologies, Inc. · R44 · FY2020 · AI
Development of a Yellow Fever Vaccine for a Vulnerable Population
$997,494Ian James Amanna · Najit Technologies, Inc. · R44 · FY2020 · AI
Development Of New Approaches To Vaccines Against TBEV and West Nile Virus
$997,471Alexander Pletnev · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Establishment/Maintenance of Biomedical Research Colony
$997,433Thomas J. Rowell · University Of Louisiana At Lafayette · U42 · FY2006 · RR
Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women
$997,413Carri Geer · Novan, Inc. · R44 · FY2020 · AI
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
$997,404Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2020 · AI
Molecular Approaches To Antiviral and Vaccine Development For Viral Hepatitis
$997,377T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
RP3: Therapeutics Human Monoclonal Antibody Treatments for Filoviruses
$997,348James E Crowe · University Of Texas Med Br Galveston · U19 · FY2018 · AI
Pre-IND Development of an Arenavirus Antiviral
$997,332Gregory William Henkel · Arisan Therapeutics, Inc. · R44 · FY2022 · AI
Defining T cell epitopes in Dengue virus infection
$997,328Ramila Philip · Immunotope, Inc. · R44 · FY2014 · AI
A NOVEL VEE REPLICON VACCINE FOR HIV
$997,238University Of North Carolina Chapel Hill · P01 · FY2004 · AI
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease
$997,077Charles T Roberts · Oregon Health & Science University · R01 · FY2025 · DK
Preclinical Development of Full Length Single Chain
$997,069Timothy R Fouts · Profectus Biosciences, Inc. · R44 · FY2011 · AI
University of Maryland BaltImore Life Science Discovery (UM-BILD) Accelerator
$997,036Jason J Rose · University Of Maryland Baltimore · U01 · FY2024 · GM
University of Maryland BaltImore Life Science Discovery (UM-BILD) Accelerator
$997,036Jason J Rose · University Of Maryland Baltimore · U01 · FY2025 · GM
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
$996,995James Forrest Kirk · Nanotherapeutics, Inc. · R44 · FY2013 · AI
DISSEMINATED TUBERCULOSIS IN HIV INFECTION
$996,915Dartmouth College · R01 · FY2004 · AI
Development of a Yellow Fever Vaccine for a Vulnerable Population
$996,895Ian James Amanna · Najit Technologies, Inc. · R44 · FY2019 · AI
Development of World's First Fully Human Broad Spectrum Anti-Snake Venom
$996,813Jacob Glanville · Centivax Inc · R44 · FY2025 · AI
Vaccines and Therapeutics for Anthrax
$996,718Stephen Leppla · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI